Latest Biotech News

Eli Lilly announced it will acquire Kelonia Therapeutics for $3.25 billion upfront, as it accelerates its in vivo cell-therapy push. The deal adds a further $3.75 billion in potential clinical,...

UCB moved to expand its epilepsy pipeline with an $1.15 billion acquisition of Neurona Therapeutics. The transaction includes a $650 million upfront payment and up to $500 million in milestone...

GSK reported positive Phase I results for mocertatug rezetecan (Mo-Rez), its B7-H4 antibody-drug conjugate, in a BEHOLD-1 study spanning platinum-resistant ovarian cancer and recurrent endometrial...

Roche will expand its cancer monitoring footprint through an acquisition of MRD testing technology from SAGA Diagnostics, with Foundation Medicine set to integrate the platform. The deal is valued...

10x Genomics launched Atera, a new in situ spatial biology platform designed to deliver whole-transcriptome profiling at high throughput while raising the bar on plex capacity. The instrument is...

Revolution Medicines reported strong Phase III data for daraxonrasib (RASolute 302) in metastatic pancreatic ductal adenocarcinoma, pushing the once-undruggable KRAS space further into the...

Nektar Therapeutics updated investors on extended mid-stage results for rezpeg in severe alopecia areata, describing deeper hair-growth outcomes with longer treatment. The company said after one...

Leinco Technologies partnered with CellCarta to combine antibody portfolios for proteomics tools used in drug development and biomarker discovery. Leinco said the collaboration pairs its antibody...

ATCC and the Broad Institute reported engineered, isogenic cancer models that replicate resistance mechanisms to targeted therapies, starting with EGFR-mutant non-small cell lung cancer treated...

Ledger Run upgraded its ClinRun platform to streamline how clinical trials manage payments to research sites for “invoiceables” — site costs that fall outside pre-set budgets and are often hard to...

Roche struck a deal to buy Saga Diagnostics for up to $595 million, and Foundation Medicine is set to expand its molecular residual disease (MRD) offering through the acquisition of Saga’s...

Exact Sciences disclosed new evidence supporting its Oncodetect MRD test in early triple-negative breast cancer, presented by collaborators at AACR. The research reported an association between...

10x Genomics launched Atera, an in situ spatial biology platform positioned for whole-transcriptome profiling with single-cell resolution and high throughput at AACR. The instrument is scheduled...

Eli Lilly agreed to buy Kelonia Therapeutics for $3.25 billion upfront, underscoring its push into in vivo CAR-T. Kelonia’s lead program is in a Phase 1 study for multiple myeloma, with an...

Novo Nordisk reported Phase 3 progress for etavopivat in sickle cell disease, saying the oral drug reduced the occurrence of pain crises and improved hemoglobin response. The company also said it...

Nektar Therapeutics said extended treatment with rezpeg produced greater hair growth in people with severe alopecia areata, supporting plans toward Phase 3. After one year, 27% of participants...

Revolution Medicines’ daraxonrasib drew market attention after data from its Phase 3 RASolute 302 trial in metastatic pancreatic ductal adenocarcinoma. The available reporting described a median...

ATCC and the Broad Institute reported engineered isogenic cancer models intended to accelerate study of resistance to targeted therapies. The initial platform focuses on osimertinib-resistant...

Almac Clinical Services released a look into how investigational drug supplies move from protocol planning through global delivery. The coverage focuses on operational controls that support...

A Sam Altman-backed startup, as described in the coverage, is raising the stakes on using AI to shorten the path to successful clinical trials, with a $1.8 billion backing figure cited in the...